{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T18:12:52.387769+00:00","company":{"ticker":"NRIX","cik":1549595,"company_name":"Nurix Therapeutics, Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"7da8c9134e083a6422bf1705c9fa619efdbd0e26","cik":1549595,"ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-04-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal quarter ended February 28, 2026","report_date":"2026-04-08","result_type":"reported_results","revenue_text":"$6.3 million"},"claim":"Nurix Therapeutics, Inc. reported the fiscal quarter ended February 28, 2026 results: revenue $6.3 million.","evidence_excerpt":"Revenue for the three months ended February 28, 2026, was $6.3 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001549595-26-000024","anchor_url":"https://secwatch.observer/filing/0001549595-26-000024#claim-7da8c9134e083a6422bf1705c9fa619efdbd0e26","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/0001549595-26-000024-index.htm"},{"fact_type":"executive_change","fact_key":"b95dfb8777","cik":1549595,"ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-10-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Anil Kapur was appointed as Director at Nurix Therapeutics, Inc..","evidence_excerpt":"On October 15, 2024, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Anil Kapur to serve as a director of the Company and as a member of the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001549595-24-000138","anchor_url":"https://secwatch.observer/filing/0001549595-24-000138#claim-b95dfb8777","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/0001549595-24-000138-index.htm"},{"fact_type":"material_agreement","fact_key":"f162d5ca548cc00e9b22fba238ba1691ecc27052","cik":1549595,"ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-04-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated","effective_date":"2024-04-11","item_codes_triggered":["1.01"],"value_text":"Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t"},"claim":"Nurix Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated valued at Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t (effective 2024-04-11).","evidence_excerpt":"On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 1,500,100 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-24-094875","anchor_url":"https://secwatch.observer/filing/0001193125-24-094875#claim-f162d5ca548cc00e9b22fba238ba1691ecc27052","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/0001193125-24-094875-index.htm"},{"fact_type":"earnings_release","fact_key":"030dc173b981d5815cea17d0a25c1b4451c2a5c7","cik":1549595,"ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-04-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended February 29, 2024","report_date":"2024-04-10","result_type":"reported_results","revenue_text":null},"claim":"Nurix Therapeutics, Inc. reported financial results for first quarter ended February 29, 2024.","evidence_excerpt":"Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.","confidence":0.96,"filing_url":"https://secwatch.observer/filing/0001549595-24-000048","anchor_url":"https://secwatch.observer/filing/0001549595-24-000048#claim-030dc173b981d5815cea17d0a25c1b4451c2a5c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000048/0001549595-24-000048-index.htm"}]}